These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 19441200)
1. [No bluff to be discovered in clinical trials]. Berglund T Lakartidningen; 2009 Mar 25-31; 106(13):952-3. PubMed ID: 19441200 [No Abstract] [Full Text] [Related]
2. [ACCOMPLISH and the risks with company sponsored clinical trials]. Furberg C Lakartidningen; 2009 Feb 11-17; 106(7):450. PubMed ID: 19350775 [No Abstract] [Full Text] [Related]
3. [A clear winner and two losers]. Furberg C Lakartidningen; 2009 Mar 25-31; 106(13):953. PubMed ID: 19441201 [No Abstract] [Full Text] [Related]
4. [Calcium antagonists--how does Furberg see them now?]. Nilsson PM Lakartidningen; 2009 Feb 25-Mar 3; 106(9):607-8; author reply 608. PubMed ID: 19388456 [No Abstract] [Full Text] [Related]
5. [Tax payers have payed billions for the "blood pressure maffia's" actions]. Järhult B; Lindahl SO Lakartidningen; 2003 May; 100(21):1917-8. PubMed ID: 12815880 [No Abstract] [Full Text] [Related]
6. Conflict of interest in the debate over calcium-channel antagonists. Strandgaard S N Engl J Med; 1998 Jun; 338(23):1697-8. PubMed ID: 9616065 [No Abstract] [Full Text] [Related]
7. [Dishonesty in clinical trials is expensive for the society 3]. Waldorff S Ugeskr Laeger; 2003 Jun; 165(26):2672-3; author reply 2673-4. PubMed ID: 12886557 [No Abstract] [Full Text] [Related]
8. [Dishonesty in clinical trials is expensive for the society 2]. Lund BA; Nordby G Ugeskr Laeger; 2003 Jun; 165(26):2672. PubMed ID: 12886556 [No Abstract] [Full Text] [Related]
9. [Dishonesty in clinical trials is expensive for the society 1]. Heslet L; Nielsen JD; Schierbeck J Ugeskr Laeger; 2003 Jun; 165(26):2671-2. PubMed ID: 12886555 [No Abstract] [Full Text] [Related]
10. Industry sponsorship in research and publishing: who is really to blame for perceived bias? Amsden GW Ann Pharmacother; 2004 Apr; 38(4):714-6. PubMed ID: 14982974 [No Abstract] [Full Text] [Related]
11. Conflict of interest in the debate over calcium-channel antagonists. Meltzer JI N Engl J Med; 1998 Jun; 338(23):1696; author reply 1697-8. PubMed ID: 9616063 [No Abstract] [Full Text] [Related]
12. [A combination of antihypertensives with various mechanisms of action]. Med Monatsschr Pharm; 2007 Mar; 30(3):120-1. PubMed ID: 17405494 [No Abstract] [Full Text] [Related]
13. Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams? Glassock RJ J Am Soc Nephrol; 2006 Dec; 17(12):3276-8. PubMed ID: 17108313 [No Abstract] [Full Text] [Related]
16. Conflict of interest in the debate over calcium-channel antagonists. Opie L N Engl J Med; 1998 Jun; 338(23):1696-7; author reply 1697-8. PubMed ID: 9616064 [No Abstract] [Full Text] [Related]
17. Benazepril plus amlodipine or hydrochlorothiazide for hypertension. Strauss MH; Weinstein J; Newton GE N Engl J Med; 2009 Mar; 360(11):1148; author reply 1149-50. PubMed ID: 19283888 [No Abstract] [Full Text] [Related]
18. Policy of the American Society of Gene Therapy on financial conflict ofinterest in clinical research. Woo SL Mol Ther; 2000 May; 1(5 Pt 1):383-4. PubMed ID: 10979736 [No Abstract] [Full Text] [Related]
20. Selecting antihypertensive medication in patients with essential hypertension in Malaysia. Ong HT; Rozina G Med J Malaysia; 2009 Mar; 64(1):3-11. PubMed ID: 19852313 [No Abstract] [Full Text] [Related] [Next] [New Search]